The FDA has cleared a phase 2 trial initiated by a researcher evaluating Cybin Inc (NYSE: CYBN) Psychedelic-assisted psychotherapy with psilocybin for frontline clinicians with COVID-related distress.
- The trial will take place at the University of Washington. It will aim to treat symptoms of depression, anxiety, burnout and post-traumatic stress disorder among doctors, nurses and frontline healthcare professionals.
- The study also received approval from the Institutional Review Board (IRB) at the University of Washington. This investigator-initiated trial will be hosted in Seattle and will be funded by several organizations.
- The phase 2 clinical trial will recruit 30 primary care clinicians.
- The primary outcome will be a comparison between the two groups for depression and anxiety, as measured by the Montgomery Asberg Depression Rating Scale (MADRS) total four weeks after the dose.
- “The lessons learned from this combined Phase 2 trial will inform the use of EMBARK in future human studies of Cybin using CYB003, a proprietary analogue of deuterated psilocybin with the potential to halve consultation times and blood levels. dosage, as well as potentially reducing side effects and adverse events, ”said Doug Drysdale, CEO.
- Price action: CYBN shares are down 5.42% to $ 1.39 in the last check trading session on Tuesday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
